Skip to main navigation Skip to search Skip to main content

Population pharmacokinetics of imatinib mesylate in healthy Korean subjects

  • Gab Jin Park
  • , Wan Su Park
  • , Soohyun Bae
  • , Sung Min Park
  • , Seunghoon Han
  • , Dong Seok Yim
  • Catholic Univ. of Korea Coll. Med.
  • The Catholic University of Korea

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Imatinib (Gleevec™; Novartis Pharmaceuticals) is an orally administered protein-tyrosine kinase inhibitor. The goal of this study was to investigate the population pharmacokinetics (PK) of imatinib (as imatinib mesylate) in healthy male Koreans. A total of 1,773 plasma samples from 112 healthy male volunteers enrolled in three phase I clinical studies were used. Among the subjects, 76 received 400 mg and 36 received 100 mg as single oral doses. Peripheral blood sampling for PK analysis was done at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 60 and 72 (at 400 mg group) h after dosing. The first-order conditional estimation with interaction method of NONMEM® (ver. 7.3) was used to build the population PK model. A two-compartment model with Weibull absorption and elimination gave the best fit to the data. The estimates of clearance (CL/F), volume of central compartment (Vc/F), inter-compartmental clearance (Q/F), peripheral volume (Vp/F) and their interindividual variabily (%CV) were 13.6 L/h (23.4%), 153 L (29.2%), 8.64 L/h (35.9%) and 64 L (67%), respectively.

Original languageEnglish
Pages (from-to)96-104
Number of pages9
JournalTranslational and Clinical Pharmacology
Volume24
Issue number2
DOIs
StatePublished - 2016

Bibliographical note

Publisher Copyright:
© 2016 Translational and Clinical Pharmacology.

Keywords

  • Imatinib
  • NONMEM
  • Population pharmacokinetics
  • Weibull

Fingerprint

Dive into the research topics of 'Population pharmacokinetics of imatinib mesylate in healthy Korean subjects'. Together they form a unique fingerprint.

Cite this